

March 25, 2021

COVID-19 Vaccine: Updated AstraZeneca and COVISHIELD Product Monographs and Health Product Risk Communication

On March 24, 2021, Health Canada updated the AstraZeneca and COVISHIELD Product Monographs, as well as issued a Health Product Risk Communication to healthcare professionals. These updates highlight that a combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been observed very rarely following vaccination with the AstraZeneca COVID-19 vaccine, and provide further guidance for healthcare professionals and vaccine recipients.

- AstraZeneca Product Monograph: <https://covid-vaccine.canada.ca/info/pdf/astrazeneca-covid-19-vaccine-pm-en.pdf>
- COVISHIELD Product Monograph: <https://covid-vaccine.canada.ca/info/pdf/covishield-pm-en.pdf>
- Health Product Risk Communication: <https://covid-vaccine.canada.ca/info/pdf/astrazeneca-covid-19-vaccine-letter.pdf>

Health Canada considers that the benefits of AstraZeneca/COVISHIELD continue to outweigh the risks (COVISHIELD is the version of the AstraZeneca vaccine currently being distributed in Canada). Health Canada is working closely with the manufacturer and international regulators to review data as it becomes available on these rare events.

Information about Manitoba's COVID-19 Immunization Program, including the above aforementioned links, can be found at: <https://www.gov.mb.ca/covid19/vaccine/index.html>.

Sincerely,



Richard Baydack, PhD
Director
Communicable Disease Control



Tim Hilderman, MD FRCPC
Medical Lead, Vaccines
Communicable Disease Control